MILPITAS, Calif., Nov. 11, 2025 – Applied StemCell, Inc. (ASC), today announced the successful knock-in of a 50 kilobase (kb) multifunctional DNA insert into human induced pluripotent stem cells (iPSCs) using its proprietary TARGATT™ technology. The achievement establishes a new benchmark for the size and complexity of genetic payloads that can be efficiently and site-specifically integrated into the human genome. [Read more…]
Bridging the Gap: Streamlining iPSC-Derived Cell Line Development from Donor Cells to MCB
Allogeneic iPSC-derived therapies hold immense promise, offering scalable, off-the-shelf solutions for a wide spectrum of diseases. However, the journey from donor cells to a gene edited, clinically compliant GMP Master Cell Bank (MCB) is fraught with challenges and is particularly vulnerable to risks stemming from misaligned early development.
A major bottleneck seen in the majority of iPSC therapeutic programs arises when development teams continue to rely on R&D grade cell lines to confirm proof-of-concept, conduct preclinical animal studies, and to start process & analytical development. [Read more…]
The Science of Extending Health and Longevity in 2026
The quest for prolonged health and longevity is a topic of great interest as we advance into 2026. With innovations in medical science and technology, we discover new methods to improve our well-being.
Many factors contribute to longevity, including genetics, lifestyle choices, diet, and access to healthcare. Researchers continue to explore the science behind these aspects, and one significant area emerges: preventive care. [Read more…]
List of Stem Cell Companies Worldwide, 2026
Stem cell companies have been rapidly populating on a global basis. Today, there surging numbers of market competitors developing stem cell therapeutics for use in humans. Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into mature cell types.
Stem cell research has been going on for over 50 years, because stem cells have a unique ability to divide and replicate repeatedly. In addition, their unspecialized nature allows them to become a wide variety of tissue types, which gives them enormous potential for use in regenerative medicine.
RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01
FREDERICK, Md. and PLANO, Texas, Oct. 6, 2025 — RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Secretome Therapeutics, a clinic-stage company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced completion of commercial scale production of Secretome’s lead nCPC, STM-01. [Read more…]
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 202
- Next Page »